Characteristics | n=316 |
Age, median (range) | 60 (28–75) |
BMI, median (range) | 28.0 (17.6–54.7) |
Histology | |
Endometrioid | 274 (86.7%) |
Serous | 22 (7%) |
Mixed | 11 (3.4%) |
Clear cell | 5 (1.6%) |
Adenocarcinoma NOS | 4 (1.3%) |
Grade | |
G1 | 58 (18.4%) |
G2 | 198 (62.6%) |
G3 | 56 (17.7%) |
Unknown | 4 (1.3%) |
Myometrial invasion | |
<50% | 151 (47.8%) |
>50% | 95 (30%) |
No | 70 (22.2%) |
FIGO stage* | |
IA | 205 (64.9%) |
IB | 66 (20.9%) |
II | 12 (3.8%) |
IIIA | 3 (0.9%) |
IIIB | 1 (0.3%) |
IIIC1 | 24 (7.6%) |
IIIC2 | 1 (0.3%) |
IVB | 4 (1.3%) |
LVSI | |
No | 264 (83.5%) |
Yes | 51 (16.2%) |
Unknown | 1 (0.3%) |
Number of SLNs per pelvic side per patient. median (range) | 1 (0–5) |
SLN mapping | |
Bilateral | 263 (83.2%) |
Unilateral | 53 (16.8%) |
Benign epithelial inclusions at ultrastaging | 17/668 (2.5%) |
*FIGO stage IIIC is reported according to lymph node positivity with both methods or by either method (isolated tumor cells considered as ‘negative’)
BMI, body mass index; FIGO, International Federation of Gynecology and Obstetrics; LVSI, lymphovascular space invasion; NOS, not otherwise specified; SLN, sentinel lymph node.